The Level of Adipo
The Level of Adiponectin in Polycystic Ovary Syndrome Patients Suffering Metabolic Syndrome
Sara Jafari *1, Mitra Niafar 2, Sajjad Hejazi3
1*Resident of Internal Medicine, Imam-Reza Hospital, Endocrine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran
2Associated Professor of Endocrinology and Metabolism, Imam-Reza Hospital, Endocrine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran
3Department of Anatomy, Tabriz branch, Islamic Azad University, Tabriz, Iran
*Corresponding author: email@example.com
Abstract: Polycystic ovary syndrome is one of the most common endocrine disorders which occurs in 6.5-8 percent of in reproductive women and is characterized by creating disorder in ovulation and hyperandrogenism. Adiponectin is one of the cytokines which is secreted by an adipose tissue; it has an anti-inflammatory effect and decreases when polycystic ovary and metabolic syndromes occur. The present study was aimed at assessing the level of Adiponectin in polycystic ovary syndrome patients who suffered metabolic syndrome. Method: The study was an analytic-descriptive one. Ninety polycystic ovary syndrome patients, 45 of whom also suffered metabolic syndrome, were selected as the study participants. Their level of Adiponectin and some other endocrine biomarkers were assessed and compared with each other. Results: Mean age of the studied patients was 24.61±6.9. Patients’ mean systolic blood pressure was 22.98±18 mmHg. The mean waist diameter in the patients was 87.2±13.34 cm. The mean level of triglyceride was 115.42±74.53mg/dl. Mean level of HDL was 48.34±16.75 mg/dl. Patients’ mean level of fasting blood glucose was 90.65±7.98 mg/dl. Mean BMI was 26.89±6.01 kg/m2. Level of Adiponectin was 11.03±3.56 mg/dl and 8.01±2.69 mg/dl in patients suffering polycystic ovary syndrome and those with polycystic ovary and metabolic syndromes, respectively. Conclusion: The results of the present study and comparing them with those of other studies showed that level of Adiponectin in patients suffering polycystic ovary syndrome is lower compared to laboratory indices which specify the normal range. Moreover, suffering metabolic syndrome in patients with polycystic ovary syndrome reduces level of Adiponectin; and comparing these two showed that there was a significant statistical difference between them (P=0.00).
[Sara Jafari, Mitra Niafar, Sajjad Hejazi. The Level of Adiponectin in Polycystic Ovary Syndrome Patients Suffering Metabolic Syndrome. Life Sci J 2013;10(7s):573-577] (ISSN:1097-8135). http://www.lifesciencesite.com. 90
Keywords: polycystic ovary syndrome, metabolic syndrome, Adiponectin.